Aurobindo Pharma Ltd (NSE:AUROPHARMA)
₹ 1221 24.65 (2.06%) Market Cap: 715.43 Bil Enterprise Value: 715.99 Bil PE Ratio: 22.55 PB Ratio: 2.40 GF Score: 93/100

Q1 2023 Aurobindo Pharma Ltd Earnings Call Transcript

Aug 12, 2022 / 03:00AM GMT
Release Date Price: ₹593.45 (+3.08%)
Operator

Ladies and gentlemen, welcome to quarter 1 FY '23 Earnings Conference Call of Aurobindo Pharma Limited. (Operator Instructions)

I now hand the conference over to Deepti Thakur. Thank you, and over to you.

Deepti Thakur

Thank you, Aditya. Good morning, and a warm welcome to our first quarter FY '23 earnings call. I'm Deepti Thakur from Investor Relations team.

We hope you have received the quarter 1 FY '22 financials and the press release that was sent out yesterday. These are also available on our website.

I would like to introduce my senior management team today on the call with us, represented by Mr. P.V. Ram Prasad Reddy , Chairman, Aurobindo Pharma USA; Mr. K. Nithyananda Reddy, Vice Chairman and Managing Director of Aurobindo Pharma Limited, Mr. S. Subramanian, CFO; Mr. Sanjeev Dani, COO, Head Formulations, Aurobindo Pharma Limited; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited; and Mr. Swami Iyer, CFO, Aurobindo Pharma USA.

We will begin the call with summary highlights from the management followed by an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot